```
> file caplus medline biosis embase japio wpix uspatful
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    21.80      22.01

FILE 'CAPLUS' ENTERED AT 09:14:21 ON 14 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:14:21 ON 14 NOV 2003

FILE 'BIOSIS' ENTERED AT 09:14:21 ON 14 NOV 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 09:14:21 ON 14 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'JAPIO' ENTERED AT 09:14:21 ON 14 NOV 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'WPIX' ENTERED AT 09:14:21 ON 14 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 09:14:21 ON 14 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 60142-96-3/rn or gabapentin or  go 3450 or goe 2450 or goe 3450 or neurontin
or 1-(aminomethyl)cyclohexaneacetic acid
MISSING OPERATOR '1-(AMINOMETHY'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s 60142-96-3/rn or gabapentin or  go 3450 or goe 2450 or goe 3450 or neurontin
or 1-aminomethyl-cyclohexaneacetic acid
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
   6 FILES SEARCHED...
L4         9118 60142-96-3/RN OR GABAPENTIN OR GO 3450 OR GOE 2450 OR GOE 3450
                OR NEURONTIN OR 1-AMINOMETHYL-CYCLOHEXANEACETIC ACID

=> s l4 or 60142-95-2/rn
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L5         9122 L4 OR 60142-95-2/RN

=> s 148553-51-9/rn or pregabalin or pd 144550 or pd 144723 or ci 1008 or
148553-50-8/rn
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L6          620 148553-51-9/RN OR PREGABALIN OR PD 144550 OR PD 144723 OR CI
                1008 OR 148553-50-8/RN

=> s l4 and l6
L7          390 L4 AND L6
```

```
=> s l7/thur
'THUR' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'THUR' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'THUR' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'THUR' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'THUR' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'THUR' IS NOT A VALID FIELD CODE
'THUR' IS NOT A VALID FIELD CODE
L8          135 L7/THUR

=> s l7 and (combination or together or combined or coadministration or
co-administration or synergistic or synergism)
L9          168 L7 AND (COMBINATION OR TOGETHER OR COMBINED OR COADMINISTRATION
                OR CO-ADMINISTRATION OR SYNERGISTIC OR SYNERGISM)

=> s l7 and (combination or together or combined or coadministration or
co-administration or synergistic or synergism or mixture)
L10         180 L7 AND (COMBINATION OR TOGETHER OR COMBINED OR COADMINISTRATION
                OR CO-ADMINISTRATION OR SYNERGISTIC OR SYNERGISM OR MIXTURE)

=> s l10 and (pain or allodynia or hyperalgesia or inflammation or inflammatory)
L11         126 L10 AND (PAIN OR ALLODYNIA OR HYPERALGESIA OR INFLAMMATION OR
                INFLAMMATORY)

=> focus l11
PROCESSING COMPLETED FOR L11
L12          126 FOCUS L11 1-

=> focus l8
PROCESSING COMPLETED FOR L8
L13          135 FOCUS L8 1-

=> d ibib abs 1-50
```

ACCESSION NUMBER: 2000390508 EMBASE
TITLE: [Antidepressants and gabapentinoids - Established and new drugs in the therapy of chronic **pain**. Preclinical and clinical studies].
ANTIDEPRESSIVA UND GABAPENTINOIDE - ETABLIERTE UND NEUE PHARMAKA IN DER BEHANDLUNG CHRONISCHER SCHMERZEN: PRAKLINISCHE UND KLINISCHE UNTERSUCHUNGEN.
AUTHOR: Eckhardt K.; Feuerstein T.J.
CORPORATE SOURCE: Dr. T.J. Feuerstein, Sekt. Klinische Neuropharmakol., Neurologische Universitatsklinik, Neurozantrum Breisocher Str. 64, D-79106 Freiburg, Germany. feuer@ukl.uni-freiburg.de
SOURCE: Nervenheilkunde, (2000) 19/8 (436-442).
Refs: 30
ISSN: 0722-1541 CODEN: NERVDI
COUNTRY: Germany
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 008 Neurology and Neurosurgery
029 Clinical Biochemistry
037 Drug Literature Index
LANGUAGE: German
SUMMARY LANGUAGE: English; German
AB Treatment of chronic **pain**, in contrast to acute **pain**, remains to be a therapeutic problem. Despite different aetiologic causes sensory neurons develop peripheral and central sensitization in the course of **pain** chronification resulting in increased sensibility (**hyperalgesia** and **allodynia**). Pathophysiological and biochemical changes follow, reflected in an altered expression and function of ion channels and receptors and finally in a changed neuronal phenotype. Tricyclic antidepressants are analgesic in different types of chronic **pain** (substance of first choice: amitriptyline), in contrast to selective serotonin reuptake inhibitors (SSRIs) with only inconsistent effects in controlled studies. Beside their known inhibition of monoamine reuptake, tricyclic antidepressants modulate ion channels, among them NMDA receptors, in the dorsal horn of the spinal cord. In controlled clinical studies **gabapentin** reduced **pain** intensity in patients suffering from chronic **pain** due to diabetic neuropathy and postherpetic neuralgia. Also **pregabalin** and **gabapentin**-lactam are antinociceptive in animal models of chronic **pain**. A predominant site of action of these drugs is probably the first nociceptive synapse where they act by diminishing glutamatergic transmission, by enhancing GABAergic transmission and by reducing the activity of nociceptive neurons through K(ATP)channels.

L17 ANSWER 90 OF 104 USPATFULL on STN

L17 ANSWER 85 OF 104 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 1999:223877 BIOSIS
DOCUMENT NUMBER: PREV199900223877
TITLE: **Gabapentin** and **pregabalin**, but not morphine and amitriptyline, block both static and dynamic components of mechanical **allodynia** induced by streptozocin in the rat.
AUTHOR(S): Field, Mark John; McCleary, Scott; Hughes, John; Singh, Lakhbir [Reprint author]
CORPORATE SOURCE: Department of Biology, Parke-Davis Neuroscience Research Centre, Cambridge University Forvie Site, Robinson Way, Cambridge, CB2 2QB, UK
SOURCE: Pain, (March, 1999) Vol. 80, No. 1-2, pp. 391-398. print. CODEN: PAINDB. ISSN: 0304-3959.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 7 Jun 1999
Last Updated on STN: 7 Jun 1999

AB A single injection of streptozocin (50 mg/kg, i.p.) led to the development of static and dynamic **allodynia** in the rat. The two responses were detected, respectively, by application of pressure using von Frey hairs or lightly stroking the hind paw with a cotton bud. Static **allodynia** was present in the majority of the animals within 10 days following streptozocin. In contrast, dynamic **allodynia** took almost twice as long to develop and was only present in approximately 60% of rats. Morphine (1-3 mg/kg, s.c.) and amitriptyline (0.25-2.0 mg/kg, p.o.) dose-dependently blocked static **allodynia**. However, neither of the compounds was effective against dynamic **allodynia**. In contrast, **gabapentin** (10-100 m-/kg, p.o.) and the related compound **pregabalin** (3-30 mg/kg, p.o.) dose-dependently blocked both types of **allodynia**. However, the corresponding R-enantiomer (10-100 mg/kg, p.o.) of **pregabalin**, was found to be inactive. The intrathecal administration of **gabapentin** dose-dependently (1-100 mug/animal) blocked both static and dynamic **allodynia**. In contrast, administration of similar doses of **gabapentin** into the hind paw failed to block these responses. It is suggested that in this model of neuropathic **pain** dynamic **allodynia** is mediated by Abeta-fibres and the static type involves small diameter nociceptive fibres. These data suggest that **gabapentin** and **pregabalin** possess a superior antiallodynic profile than morphine and amitriptyline, and may represent a novel class of therapeutic agents for the treatment of neuropathic **pain**.

L17 ANSWER 86 OF 104 USPATFU

L17 ANSWER 65 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:141204 CAPLUS
DOCUMENT NUMBER: 130:191891
TITLE: GABA analogs to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome
INVENTOR(S): Guglietta, Antonio; Taylor, Charles, Price, Jr.; Ren, Jiayuan; Watson, W. P.; Rafferty, Michael Francis; Diop, Laurent; Chovet, Maria; Bueno, Lionel; Little, Hilary J.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; The University of Oklahoma
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9908671	A1	19990225	WO 1998-US17082	19980818
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9892930	A1	19990308	AU 1998-92930	19980818
EP 1009399	A1	20000621	EP 1998-945758	19980818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9812133	A	20000718	BR 1998-12133	19980818
JP 2001515033	T2	20010918	JP 2000-509411	19980818
CA 2297163	C	20011120	CA 1998-2297163	19980818
NZ 502729	A	20021025	NZ 1998-502729	19980818
ZA 9807493	A	19990707	ZA 1998-7493	19980819
US 6127418	A	20001003	US 1999-284710	19990419
MX 200001093	A	20001020	MX 2000-1093	20000131
NO 2000000786	A	20000217	NO 2000-786	20000217
US 6242488	B1	20010605	US 2000-567191	20000509
US 2001014698	A1	20010816	US 2001-804742	20010313
US 6426368	B2	20020730		

PRIORITY APPLN. INFO.:
US 1997-56753P P 19970820
US 1998-74794P P 19980216
US 1998-82936P P 19980424
WO 1998-US17082 W 19980818
US 1999-284710 A3 19990419
US 2000-567191 A3 20000509

OTHER SOURCE(S): MARPAT 130:191891

AB GABA analogs are useful to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome. Preferred treatments employ **gabapentin** or **pregabalin**.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 66 OF 104 USPATFULL on ST

L17 ANSWER 62 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:678656 CAPLUS
DOCUMENT NUMBER: 139:202522
TITLE: **Combinations** of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
INVENTOR(S): Taylor, Charles Price, Jr.
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070237	A1	20030828	WO 2003-IB534	20030212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003199567	A1	20031023	US 2003-366798	20030214

PRIORITY APPLN. INFO.: US 2002-359295P P 20020222
US 2002-404365P P 20020819

AB The invention relates to a **combination**, comprising a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, and a ligand for calcium channel .alpha.2.delta. subunit, or a pharmaceutically acceptable salt thereof, and valdecoxib. Examples of selective inhibitors of COX-2 include valdecoxib, rofecoxib, and celecoxib. Examples of .alpha.2.delta. ligands include **gabapentin**, **pregabalin**, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, and 3-(1-aminomethyl-cyclohexymethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride (I). The **combinations** are useful for treating certain diseases including cartilage damage, **inflammation**, **pain**, and arthritis. For example, capsules contg. 25 mg each of valdecoxib and I were prepd.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 56 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:905785 CAPLUS
DOCUMENT NUMBER: 137:389160
TITLE: Liquid pharmaceutical composition containing GABA analogs and polyhydric alcohols
INVENTOR(S): Kulkarni, Neema Mahesh; Schneider, Michael; Silbering, Steven Bernard; Meyer-wonnay, Hans Richard
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094220	A1	20021128	WO 2002-IB1500	20020429
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002198261	A1	20021226	US 2002-156213	20020528

PRIORITY APPLN. INFO.: US 2001-293832P P 20010525
US 2001-343733P P 20011025

AB A liq. pharmaceutical compn. of a GABA analog comprising at least one polyhydric alc. contg. 2 to 6 carbon atoms having a pH of about 5.5 to about 7.0 and addnl. a two-component liq. pharmaceutical compn. comprising a first component comprising a powder **mixt**. comprising a GABA analog and a solid polyhydric alc., and a second component comprising a liq. base are described, as well as methods to prep. the compns. and a method for treating cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, **inflammation**, renal colic, insomnia, gastrointestinal damage, incontinence, **pain**, including neuropathic **pain**, muscular **pain**, skeletal **pain**, and migraine using a therapeutically effective amt. of the pharmaceutical compns. A liq. compn. contained **gabapentin**, xylitol, glycerol, flavors and water.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 39 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:633456 CAPLUS
DOCUMENT NUMBER: 139:154954
TITLE: Medicinal compositions containing **gabapentin** or **pregabalin** and N-type calcium channel antagonist
INVENTOR(S): Iwayama, Satoshi; Koganei, Hajime; Fujita, Shinichi; Takeda, Tomoko; Yamamoto, Hiroshi; Niwa, Seiji
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066040	A1	20030814	WO 2003-JP1163	20030205

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-28208 A 20020205
JP 2002-111068 A 20020412
JP 2002-317480 A 20021031
OTHER SOURCE(S): MARPAT 139:154954
AB Disclosed are medicinal compns. useful as preventives/remedies for **pain** which comprise **gabapentin**, **pregabalin** or pharmaceutically acceptable salts thereof **combined** with N-type calcium channel antagonists or pharmaceutically acceptable salts thereof having specified structures. A compd. N-[3-[4-(5H-dibenzo[a,d][7]annulene-5-ylidene)-1-piperidinyl]-3-oxopropyl]-2,2-dimethylpropanamide (I) was prepd. The analgesic effect of oral administration of **gabapentin** 100 mg/kg **combined** with the compd. I 3 mg/kg in **pain** rat model was examd.
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 36 OF 104 USPATFULL on STN
ACCESSION NUMBER: 2001:226682 USPATFULL
TITLE: Use of GABA analogs such as **Gabapentin** in the manufacture of a medicament for treating **inflammatory** diseases
INVENTOR(S): Schrier, Denis, Ann Arbor, MI, United States
Taylor, Jr., Charles Price, Chelsea, MI, United States
Westlund High, Karin Nanette, League City, TX, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6329429	B1	20011211	
	WO 9858641		19981230	
APPLICATION INFO.:	US 1999-403867		19991025	(9)
	WO 1998-US13107		19980624	
			19991025	PCT 371 date
			19991025	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-50736P	19970625 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Geist, Gary
ASSISTANT EXAMINER: Deemie, Robert W.
LEGAL REPRESENTATIVE: Ashbrook, Charles W., Purchase, Jr., Claude F.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 603
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB GABA analogs such as **gabapentin** and **pregabalin** are useful to prevent and treat **inflammatory** diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 37 OF 104 USPATFULL on STN
ACCESSION NUMBER: 2002:55072 USPATFULL
TITLE: Anti-**inflammatory** method
INVENTOR(S): Schrier, Denis, Ann Arbor, MI, UNITED STATES
Taylor, Charles Price, JR., Chelsea, MI, UNITED STATES
High, Karin Nanette Westlund, League City, TX, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002032235	A1	20020314	
APPLICATION INFO.:	US 2001-924656	A1	20010808	(9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-403867, filed on 25 Oct 1999, PENDING A 371 of International Ser. No. WO 1998-US13107, filed on 24 Jun 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-50736P	19970625 (60)
	US 1998-84183P	19980504 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105
NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB GABA analogs such as **gabapentin** and **pregabalin** are useful to prevent and treat **inflammatory** diseases.

L17 ANSWER 32 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:202474 CAPLUS
DOCUMENT NUMBER: 138:215340
TITLE: Pharmaceutical composition comprising **gabapentin** or an analogue thereof and an .alpha.-aminoamide, and its analgesic use
INVENTOR(S): Salvati, Patricia; Veneroni, Orietta; Maj, Roberto; Fariello, Ruggero; Benatti, Luca
PATENT ASSIGNEE(S): Newron Pharmaceuticals S.p.A., Italy
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020273	A2	20030313	WO 2002-EP8910	20020809
WO 2003020273	A3	20030904		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1287853	A1	20030305	EP 2001-121069	20010903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: EP 2001-121069 A 20010903

AB A pharmaceutical compn. for analgesic use is disclosed which comprises **gabapentin** or an analog thereof (**pregabalin** or tiagabine) and an .alpha.-aminoamide. A **synergistic** effect of the resp. analgesic activities without concomitant increase of side effects was obsd.

L17 ANSWER 33 OF 104 USPATFULL o

L17 ANSWER 22 OF 104 USPATFULL on STN

ACCESSION NUMBER:	2002:239059 USPATFULL			
TITLE:	Analgesic compositions comprising anti-epileptic compounds and methods of using same			
INVENTOR(S):	Hurtt, Mark Richard, Ann Arbor, MI, United States Mundel, Trevor, Ann Arbor, MI, United States			
PATENT ASSIGNEE(S):	Warner-Lambert Company, Mottis Plains, NJ, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6451857	B1	20020917	
	WO 2000053225		20000914	
APPLICATION INFO.:	US 2001-936394		20010910	(9)
	WO 2000-US2080		20000127	
			20010910	PCT 371 date
	NUMBER		DATE	
PRIORITY INFORMATION:	US 1999-123739P		19990310 (60)	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Henley, III, Raymond			
LEGAL REPRESENTATIVE:	Richardson, Peter C., Ashbrook, Charles W., DeBenedictis, Karen			
NUMBER OF CLAIMS:	6			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)			
LINE COUNT:	509			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel **combinations** of one or more anti-epileptic compounds that demonstrate **pain** alleviating properties, with one or more compounds selected from the group consisting of analgesics, NMDA receptor antagonists, NSAIDs, and **combinations** thereof, and pharmaceutical compositions comprising same. It has been discovered that the administration of anti-epileptic compounds that demonstrates **pain** alleviating properties in these novel **combinations** results in an improved reduction in the frequency and severity of **pain**. It is also believed that the incidence of unwanted side effects can be reduced by these novel **combinations** in comparison to using higher doses of a single agent treatment to achieve a similar therapeutic effect. The present invention is also directed to methods of using effective amounts of the novel pharmaceutical compositions to treat **pain** in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 104 USPATFULL on STN

ACCESSION NUMBER: 2001:82813 USPATFULL

TITLE: Method for preventing and treating **pain**

INVENTOR(S): Bueno, Lionel, Aussonne, France
Chovet, Maria, Montrouge, France
Diop, Laurent, Saclay, France
Guglietta, Antonio, Ann Arbor, MI, United States
Little, Hilary J., County Durham, United Kingdom
Rafferty, Michael Francis, Ann Arbor, MI, United States
Ren, Jiayuan, Oklahoma City, OK, United States
Taylor, Jr., Charles Price, Chelsea, MI, United States
Watson, William Patrick, Meadowfield, United Kingdom

PATENT ASSIGNEE(S): University of Oklahoma, Oklahoma City, OK, United States (U.S. corporation)
Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6242488	B1	20010605
APPLICATION INFO.:	US 2000-567191		20000509 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 284710, now patented, Pat. No. US 6127418, issued on 3 Oct 2000

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Henley, III, Raymond

LEGAL REPRESENTATIVE: Ashbrook, Charles W.

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 929

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB GABA analogs are useful to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome. Preferred treatments employ **gabapentin** or **pregabalin**.

L17 ANSWER 9 OF 104 USPATFULL on STN
ACCESSION NUMBER: 2003:283223 USPATFULL
TITLE: **Combinations** of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
INVENTOR(S): Taylor, Charles Price, JR., Chelsea, MI, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003199567	A1	20031023	
APPLICATION INFO.:	US 2003-366798	A1	20030214	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-359295P	20020222	(60)
	US 2002-404365P	20020819	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 3821
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a **combination**, comprising a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, and an Alpha-2-delta ligand, or a pharmaceutically acceptable salt thereof, and valdecoxib. Examples of selective inhibitors of COX-2 include valdecoxib, rofecoxib, and celecoxib. Examples of Alpha-2-delta ligands include **gabapentin**, **pregabalin**, (3S,4S)-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, and 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride. The **combinations** are useful for treating certain diseases including cartilage damage, **inflammation**, **pain**, and arthritis.

L17 ANSWER 7 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:721127 CAPLUS

DOCUMENT NUMBER: 138:281015

TITLE: **Gabapentin** and **pregabalin** suppress tactile **allodynia** and potentiate spinal cord stimulation in a model of neuropathy

AUTHOR(S): Wallin, Johan; Cui, Jian-Guo; Yakhnitsa, Vadim; Schechtmann, Gaston; Meyerson, Bjoern A.; Linderoth, Bengt

CORPORATE SOURCE: Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institutet, Stockholm, Swed.

SOURCE: European Journal of Pain (London, United Kingdom) (2002), 6(4), 261-272
CODEN: EJPAFJ; ISSN: 1090-3801

PUBLISHER: W. B. Saunders

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Spinal cord stimulation (SCS) is an effective tool in alleviating neuropathic **pain**. However, a no. of well-selected patients fail to obtain satisfactory **pain** relief. Previous studies have demonstrated that i.t. baclofen and/or adenosine can enhance the SCS effect, but this **combined** therapy has been shown to be useful in less than half of the cases and more effective substances are therefore needed. The aim of this exptl. study in rats was to examine whether **gabapentin** or **pregabalin** attenuates tactile **allodynia** following partial sciatic nerve injury and whether subeffective doses of these drugs can potentiate the effects of SCS in rats which do not respond to SCS. Mononeuropathy was produced by a photochem. induced ischemic lesion of the sciatic nerve. Tactile withdrawal thresholds were assessed with von Frey filaments. Effects of increasing doses of **gabapentin** and **pregabalin** (i.t. and i.v.) on the withdrawal thresholds were analyzed. These drugs were found to reduce tactile **allodynia** in a dose-dependent manner. In SCS non-responding rats, i.e., where stimulation per se failed to suppress **allodynia**, a **combination** of SCS and subeffective doses of the drugs markedly attenuated **allodynia**. In subsequent acute expts., extracellular recordings from wide dynamic range neurons in the dorsal horn showed prominent hyperexcitability. The **combination** of SCS and **gabapentin**, at the same subeffective dose, clearly enhanced suppression of this hyperexcitability. In conclusion, elec. therapy and pharmacol. therapy in neuropathic **pain** can, when they are inefficient individually, become effective when **combined**.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT